Evidence map›Paper›PMID 40135846›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Lycium barbarum Glycopeptide Alleviates Neomycin-Induced Ototoxicity by Inhibiting Tryptophan Hydroxylase-Mediated Serotonin Biosynthesis.

Yunhao Wu, Li Zhang, Shengda Cao, Jingwen Zhang, Cheng Li, Yunlong Shan, Qiuping Liu, Zhexiong Yu, Qiaojun Fang, Yuhua Zhang and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Yunhao WuMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China.ORCID https://orcid.org/0009-0001-0168-6847
Li ZhangKey Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, 510632, China.
Shengda CaoDepartment of Otorhinolaryngology, Qilu Hospital of Shandong University, NHC Key Laboratory of Otorhinolaryngology (Shandong University), Jinan, 250063, China.
Jingwen ZhangDepartment of Otolaryngology-Head and Neck, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China.
Cheng LiYixing Traditional Chinese Medicine Hospital, Yixing, 214299, China.
Yunlong ShanKey Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Qiuping LiuDepartment of Otolaryngology-Head and Neck Surgery, Affiliated Hospital of Jiangnan University, Wuxi, 214000, China.
Zhexiong YuTianren Goji Biotechnology Co., Ltd, Ningxia, 755000, China.
Qiaojun FangDepartment of Otolaryngology-Head and Neck Surgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Yuhua ZhangDepartment of Otolaryngology-Head and Neck Surgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
Xiaolong FuMedical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250000, China.
Kwok-Fai SoGuangdong-Hongkong-Macau Institute of Central Nervous System (CNS) Regeneration, Ministry of Education Central Nervous System (CNS) Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou, 510632, China.
Renjie ChaiState Key Laboratory of Digital Medical Engineering, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Jiangsu Province High-Tech Key Laboratory for Bio-Medical Research, Southeast University, Nanjing, 210096, China.ORCID https://orcid.org/0000-0002-3885-543X

Funding

National Key Research and Development Program of China 2020YFA0112503National Key Research and Development Program of China 2020YFA0113600National Key Research and Development Program of China 2021YFA1101300National Key Research and Development Program of China 2021YFA1101800National Natural Science Foundation of China 81970882National Natural Science Foundation of China 82030029National Natural Science Foundation of China 82101228National Natural Science Foundation of China 92149304Open Research Fund of State Key Laboratory of Genetic Engineering, Fudan University SKLGE-2104Science and Technology Department of Sichuan Province 2021YFS0371Shenzhen Science and Technology Program JCYJ20190814093401920Shenzhen Science and Technology Program JCYJ20210324125608022STI2030-Major Projects 2022ZD0207600Strategic Priority Research Program of the Chinese Academy of Science XDA16010303Young Scientists Fund of Shandong First Medical University (Shandong Academy of Medical Sciences) XJ20240065
6 · The paper itself

Abstract

Aminoglycoside antibiotic-induced sensorineural hearing loss (SNHL) is a common sensory disorder that requires the development of prophylactic and therapeutic interventions. Lycium barbarum glycopeptide (LBGP) is a peptidoglycan isolated and purified from Lycium barbarum polysaccharides that exhibit significant anti-inflammatory, antioxidant, and neuroprotective effects, but the role of LBGP in aminoglycoside-induced SNHL has not been well investigated. Here it is shown that LBGP can protect against neomycin-induced hearing impairment and alleviate oxidative stress in a neomycin-induced SNHL mouse model. Moreover, it is further found that inhibition of tryptophan hydroxylase (Tph)-mediated serotonin (5-HT) biosynthesis plays a key role in the mechanism of action of LBGP in treating neomycin-induced hearing loss. Systemic delivery of 5-HT increased neomycin-induced apoptosis of cochlear hair cells and spiral ganglion neurons, and pharmacological Tph2 inhibition with P-chlorophenylalanine or Tph2 knock down by AAV-ie-Tph2 effectively attenuated neomycin-induced hearing dysfunction. Collectively, these results provide a promising strategy for the prevention of SNHL by using natural plant extract which is more available and exhibits lower side effects compared with other otoprotective drugs, and identify Tph2 as a potential pharmacological target for the treatment of aminoglycoside-induced ototoxicity.

Indexed as

Drugs, Chinese HerbalGlycopeptidesHearing Loss, SensorineuralNeomycinOtotoxicitySerotoninTryptophan HydroxylaseAnimalsDisease Models, AnimalHair Cells, AuditoryLyciumMaleMiceMice, Inbred C57BLOxidative StressDrugs, Chinese HerbalGlycopeptidesNeomycinSerotoninTryptophan HydroxylaseLycium barbarum glycopeptideP‐chlorophenylalaninesensorineural hearing losstryptophan hydroxylasetryptophan metabolism

Identifiers

PMID40135846
PMCPMC12362758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.